Phase ii study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion spect-based imaging agent (99mtc-etarfolatide)

Annals of Oncology

Volumn 25, Issue 4, 2014, Pages 852-858

  Morris, R T ^a   Joyrich, R N ^b   Naumann, R W ^c   Shah, N P ^d   Maurer, A H ^e   Strauss, H W ^f   Uszler, J M ^g   Symanowski, J T ^c   Ellis, P R ^h   Harb, W A ⁱ  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c LEVINE CANCER INSTITUTE   (United States)

^d CAROLINAS MEDICAL CENTER   (United States)

^e TEMPLE UNIVERSITY HOSPITAL   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g SAINT JOHN'S HEALTH CENTER   (United States)

^h Endocyte Inc   (United States)

ⁱ Horizon Oncology Research Inc   (United States)

Author keywords

Recurrent ovarian cancer; Vintafolide

Indexed keywords

ETARFOLATIDE TC 99M; FOLATE RECEPTOR; VINTAFOLIDE; FOLATE RECEPTOR 1; FOLIC ACID; TECHNETIUM 99M ETARFOLATIDE; TECHNETIUM COMPLEX; VINCA ALKALOID;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CONTROL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EXPLORATORY RESEARCH; FATIGUE; FEMALE; HUMAN; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; RADIOGRAPHY;

ADULT; AGED; DIAGNOSTIC IMAGING; FEMALE; FOLATE RECEPTOR 1; FOLIC ACID; HUMANS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; ORGANOTECHNETIUM COMPOUNDS; OVARIAN NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VINCA ALKALOIDS;

EID: 84897043920     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu024     Document Type: Article

References (12)

1. Weitman SD, Lark RH, Coney LR et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 2006;52:3396-3401.
2. Ross JF, Chaudhuri PK, Ratnam N. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994;73:2432-2443.
3. Toffoli G, Russo A, Gallo A et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 1998;79:121-126.
4. Parker N, Turk MJ, Westrick E et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-293.
5. Leamon CP. Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs 2008;9:1277-1286.
6. Leamon CP, Jackman AL. Exploitation of the folate receptor in the management of cancer and inflammatory disease. Vitam Horm 2008;79:203-233.
7. Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 2007;26:111-128.
8. Leamon CP, Reddy JA, Vlahov IR et al. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. Int J Cancer 2007; 121:1585-1592.
9. Leamon CP, Parker MA, Vlahov IR et al. Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical. Bioconjug Chem 2002;13:1200-1210.
10. Reddy JA, Xu LC, Parker N et al. Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. J Nucl Med 2004;45:857-866.
11. Fisher RE, Siegel BA, Edell SL et al. Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med 2008; 49:899-906.
12. Naumann RW, Coleman RL, Burger RA et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol 2013;31:4400-4406.